

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/014677 A9

(43) International Publication Date
09 February 2023 (09.02.2023)

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 47/61 (2017.01)
A61K 31/713 (2006.01) C07H 21/02 (2006.01)

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/039111

(22) International Filing Date:

02 August 2022 (02.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/228,830 03 August 2021 (03.08.2021) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.

[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, MA 02142 (US).

(72) Inventors: SCHLEGEL, Mark, K.; 675 West Kendall

Street, Henri A. Termeer Square, Cambridge, MA 02142
(US). CASTORENO, Adam; 675 West Kendall Street,
Henri A. Termeer Square, Cambridge, MA 02142 (US).
MCININCH, James, D.; 675 West Kendall Street, Henri
A. Termeer Square, Cambridge, MA 02142 (US).

(74) Agent: ZACHARAKIS, Maria, Laccotripe et al.; Mc-

Carter & English, LLP, 265 Franklin Street, Boston, MA
02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

04 January 2024 (04.01.2024)

(15) Information about Correction:

see Notice of 04 January 2024 (04.01.2024)

(54) Title: TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the transthyretin (TTR) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an TTR gene and to methods of preventing and treating an TTR-associated disorder, e.g., senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia.



WO 2023/014677 A9